NASDAQ$PTCT
PTC Therapeutics, Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
PTC Therapeutics reported strong revenue performance across its product portfolio and achieved planned clinical and regulatory milestones in Q1 2024.
PTC Therapeutics announced a strong start to 2024, with total revenues of $210.1 million for the first quarter, driven by solid commercial performance and the achievement of key clinical and regulatory milestones, including the submission of the MAA for sepiapterin and the BLA for Upstaza.
- Total revenues for the first quarter of 2024 were $210.1 million, compared to $220.4 million for the first quarter of 2023.
- DMD franchise revenue was $161 million, with Translarna net product revenue at $104 million and Emflaza net product revenue at $57 million.
- The company submitted an MAA to the EMA for sepiapterin for PKU and a BLA to the FDA for Upstaza for AADC deficiency in March 2024.
- PTC reaffirmed its full-year 2024 total revenue guidance to be between $600 million and $680 million.
Headline financials
Revenue & EPS history
PTC Therapeutics · Revenue · Quarterly
$210M
Revenue by segment
PTC Therapeutics · $136M total across 2 segments · Q3 2023
- Translarna$69M-10.4%50.6%
- Emflaza$67.4M+22.5%49.4%
Forward guidance
PTC anticipates total revenues for full year 2024 to be between $600 million and $680 million. PTC anticipates GAAP R&D and SG&A expense for full year 2024 to be between $740 and $835 million. PTC anticipates Non-GAAP R&D and SG&A expense for full year 2024 to be between $660 and $755 million, including expected R&D expense milestone payments of up to $65 million and excluding estimated non-cash, stock-based compensation expense of $80 million.
Tailwinds
- Full year 2024 total revenue is expected to be between $600 million and $680 million.
- GAAP R&D and SG&A expenses are projected to be between $740 million and $835 million.
- Non-GAAP R&D and SG&A expenses are anticipated to be between $660 million and $755 million.
- Includes up to $65 million in expected R&D expense milestone payments.
- Excludes an estimated $80 million in non-cash, stock-based compensation expense.
Headwinds
- Full year revenue guidance indicates a potential decrease compared to the previous year.
- GAAP R&D and SG&A expenses are expected to remain high, impacting profitability.
- Non-GAAP expenses, while lower, still represent a significant investment in R&D and SG&A.
- Milestone payments could further strain financials if regulatory and sales targets are met.
- Stock-based compensation expense continues to be a significant non-cash expense.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2024
-2.2%
Avg return
Earnings day
+1.2%
Avg return
5 days after
+5.8%
Avg return
30 days after
46%
26 / 57 earnings
Positive
+24.1%
Q2 2016
Best reaction
-34.0%
Q3 2016
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.2% | +14.0% | +10.1% | |
| Q4 2025 | +1.1% | -3.1% | -6.6% | |
| Q3 2025 | -1.1% | +3.3% | +6.4% | |
| Q1 2025 | +12.8% | +27.1% | +44.0% | |
| Q4 2024 | +9.3% | +2.7% | +7.3% | |
| Q3 2024 | +2.5% | +3.3% | +11.3% | |
| Q2 2024 | -1.8% | +0.1% | -1.0% | |
| Q1 2024 | +13.3% | +27.5% | +47.6% | |
| Q4 2023 | +13.3% | +11.0% | +3.2% | |
| Q3 2023 | -20.5% | -19.5% | -6.9% | |
| Q2 2023 | -3.7% | -2.9% | -0.3% | |
| Q1 2023 | +5.6% | +5.2% | -18.3% | |
| Q4 2022 | -5.2% | -7.4% | -0.0% | |
| Q3 2022 | -15.7% | -17.3% | -12.9% | |
| Q2 2022 | +11.9% | +8.2% | +8.5% | |
| Q1 2022 | +1.5% | -7.8% | -24.9% | |
| Q4 2021 | -8.8% | -8.7% | -4.1% | |
| Q3 2021 | +7.0% | +12.4% | +7.4% | |
| Q2 2021 | -2.9% | -2.3% | +7.3% | |
| Q1 2021 | +0.3% | -1.3% | -5.6% | |
| Q4 2020 | -0.9% | -0.5% | -14.6% | |
| Q3 2020 | -0.5% | +8.4% | +22.0% | |
| Q2 2020 | -3.0% | -0.9% | -1.0% | |
| Q1 2020 | -10.3% | -7.9% | -5.3% | |
| Q4 2019 | -5.4% | +0.4% | -18.7% | |
| Q3 2019 | +1.9% | +2.4% | +16.8% | |
| Q2 2019 | +8.6% | +10.4% | +1.5% | |
| Q1 2019 | +1.4% | -1.2% | +10.5% | |
| Q4 2018 | +0.9% | -0.7% | +6.8% | |
| Q3 2018 | -12.4% | -14.9% | -13.4% | |
| Q2 2018 | +7.2% | +14.9% | +15.4% | |
| Q1 2018 | -4.7% | -2.6% | +22.8% | |
| Q4 2017 | +10.0% | +8.0% | -2.4% | |
| Q3 2017 | -1.9% | -5.2% | -11.2% | |
| Q2 2017 | -2.1% | -4.7% | +4.3% | |
| Q1 2017 | -3.8% | +6.6% | +26.3% | |
| Q4 2016 | -16.9% | -23.2% | -4.8% | |
| Q3 2016 | -34.0% | -11.2% | +74.5% | |
| Q2 2016 | +24.1% | +24.6% | +26.4% | |
| Q1 2016 | +1.7% | — | — | |
| Q4 2015 | -30.5% | — | — | |
| Q3 2015 | +4.3% | — | — | |
| Q2 2015 | +0.4% | — | — | |
| Q1 2015 | -11.2% | — | — | |
| Q4 2014 | -4.3% | — | — | |
| Q3 2014 | +3.3% | — | — | |
| Q2 2014 | -12.5% | — | — | |
| Q1 2013 | -5.7% | — | — | |
| Q1 2014 | -5.7% | — | — | |
| Q4 2013 | -8.4% | — | — | |
| Q1 2012 | -8.4% | — | — | |
| Q4 2011 | -8.4% | — | — | |
| Q3 2012 | -10.7% | — | — | |
| Q3 2013 | -10.7% | — | — | |
| Q2 2013 | +1.2% | — | — | |
| Q2 2012 | +1.2% | — | — | |
| Q4 2012 | +1.2% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro